Efficacy of pioglitazone in the treatment of metabolic dysfunction-associated fatty liver disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202502652902049

Enrollment

150

Registered

2025-02-03

Start date

2022-06-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

placebo group

Pioglitazone group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Age : more than 18 y. • MAFLD diagnosis by an imaging study ( Ultrasound and Fibroscan ).

Exclusion criteria

Exclusion criteria: • Chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV). • Uncontrolled hypo- or hyperthyroidism. • Liver disease for any other cause. • Allergy to medication in our study. • Pregnancy and breastfeeding. • Psychiatric disorders. • Congestive heart failure. • Chronic kidney disease.

Design outcomes

Primary

Measure	Time frame
improvement of MAFLD by fibro scan	—

Secondary

Measure	Time frame
side effects and safety of pioglitazone	—

Countries

Egypt

Contacts

Public ContactAmr hassan

alazhar university assuit

amrelgatet2003@gmail.com00201013712039

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026